- 2024-08-20 01:46抑制剂B7/CD28 interaction inhibitor 1|B7/CD28 interaction inhibitor 1|635324-72-0|Adamas life|≥98%（以实测数
- 2024-08-20 01:46抑制剂B7/CD28 interaction inhibitor 1|B7/CD28 interaction inhibitor 1|635324-72-0|Adamas life|≥98%（以实测数
- 2024-08-20 01:46抑制剂B7/CD28 interaction inhibitor 1|B7/CD28 interaction inhibitor 1|635324-72-0|Adamas life|≥98%（以实测数
- 2024-08-20 01:46抑制剂Azetidine-2-carboxylic acid|Azetidine-2-carboxylic acid|2517-04-6|Adamas life|≥98%（以实测数值为准）|BR|50
- 2024-08-20 01:46抑制剂Azoramide|Azoramide|932986-18-0|Adamas life|≥98%（以实测数值为准）|BR|100mg
- 2024-08-20 01:46抑制剂Azoramide|Azoramide|932986-18-0|Adamas life|≥98%（以实测数值为准）|BR|25mg
- 2024-08-20 01:46抑制剂Azoramide|Azoramide|932986-18-0|Adamas life|≥98%（以实测数值为准）|BR|5mg
- 2024-08-20 01:46抑制剂AZD-9574|AZD-9574|2756333-39-6|Adamas life|≥98%（以实测数值为准）|BR|25mg
- 2024-08-20 01:46抑制剂AZD-9574|AZD-9574|2756333-39-6|Adamas life|≥98%（以实测数值为准）|BR|5mg
- 2024-08-20 01:46抑制剂Azetidine-2-carboxylic acid|Azetidine-2-carboxylic acid|2517-04-6|Adamas life|≥98%（以实测数值为准）|BR|10
- 2024-08-20 01:46抑制剂Azetidine-2-carboxylic acid|Azetidine-2-carboxylic acid|2517-04-6|Adamas life|≥98%（以实测数值为准）|BR|1g
- 2024-08-20 01:46抑制剂AZD-8529|AZD-8529|1092453-15-0|Adamas life|≥98%（以实测数值为准）|BR|25mg
- 2024-08-20 01:46抑制剂AZD-8529|AZD-8529|1092453-15-0|Adamas life|≥98%（以实测数值为准）|BR|5mg
- 2024-08-20 01:46抑制剂AZD-9574|AZD-9574|2756333-39-6|Adamas life|≥98%（以实测数值为准）|BR|1mg
- 2024-08-20 01:46抑制剂AZD8330|AZD8330|869357-68-6|Adamas life|≥98%（以实测数值为准）|BR|25mg
- 2024-08-20 01:46抑制剂AZD8330|AZD8330|869357-68-6|Adamas life|≥98%（以实测数值为准）|BR|5mg
- 2024-08-20 01:46抑制剂AZD-8529|AZD-8529|1092453-15-0|Adamas life|≥98%（以实测数值为准）|BR|1mg
- 2024-08-20 01:46抑制剂AZD-8055|AZD-8055|1009298-09-2|Adamas life|≥98%（以实测数值为准）|BR|5mg
- 2024-08-20 01:46抑制剂AZD8330|AZD8330|869357-68-6|Adamas life|≥98%（以实测数值为准）|BR|100mg
- 2024-08-20 01:46抑制剂AZD-8055|AZD-8055|1009298-09-2|Adamas life|≥98%（以实测数值为准）|BR|25mg
